Immune drugs based on programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade provide a new choice for the treatment of patients with postoperative recurrence or metastasis of GI tumors. This evidence concerns the gene PDCD1 and digestive system neoplasm.